MedTrace Logo

YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus

NCT01836172 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2016-08-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the treatment of endothelial dysfunction in patients with diabetes mellitus.

Conditions

  • Diabetic Complication

Interventions

DRUG

YJP-14

An 50% ethanolic extract of Lindera obtusiloba stems

Sponsors & Collaborators

  • Han Wha Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Byung-Hee Oh, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01836172 on ClinicalTrials.gov